(UBI) Ubisoft Entertainment - Ratings and Ratios
Video Games, Game Engines, Software Tools
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 63.3% |
| Value at Risk 5%th | 81.3% |
| Relative Tail Risk | -21.97% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.90 |
| Alpha | -54.88 |
| CAGR/Max DD | -0.39 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.485 |
| Beta | 0.549 |
| Beta Downside | 0.907 |
| Drawdowns 3y | |
|---|---|
| Max DD | 80.96% |
| Mean DD | 41.01% |
| Median DD | 41.84% |
Description: UBI Ubisoft Entertainment January 18, 2026
Ubisoft Entertainment SA develops, publishes, distributes and operates video-game titles across consoles, PC, smartphones and tablets, selling both physical copies and digital downloads worldwide. Founded in 1986 and based in Saint-Mandé, France, the firm creates all core software components-from narrative scripts and animation to gameplay mechanics and proprietary game-engine tools.
Key financial indicators show Ubisoft generated roughly €2.2 billion in revenue for FY 2023, with an operating margin hovering around 6 % and free-cash-flow conversion of about 45 % of earnings. The company’s growth is increasingly tied to “live-service” titles (e.g., *Rainbow Six* and *The Division* series), which drive recurring subscription and micro-transaction revenue-a sector trend that has lifted average revenue per user (ARPU) by an estimated 12 % YoY.
Ubisoft operates in the Interactive Home Entertainment sub-industry (GICS), a market projected to expand at ~8 % CAGR through 2027, buoyed by rising console adoption cycles and the shift toward cloud-gaming platforms. The firm’s balance sheet remains relatively modest, with net debt below €400 million, giving it flexibility to invest in new IP and strategic acquisitions.
For a deeper quantitative view of Ubisoft’s valuation metrics, the ValueRay platform offers a concise dashboard of forward multiples and cash-flow projections.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: -128.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.32 > 0.02 and ΔFCF/TA 43.07 > 1.0 |
| NWC/Revenue: 4.41% < 20% (prev 23.02%; Δ -18.61% < -1%) |
| CFO/TA 0.34 > 3% & CFO 1.45b > Net Income -128.3m |
| Net Debt (-668.2m) to EBITDA (563.9m): -1.18 < 3 |
| Current Ratio: 1.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (131.2m) vs 12m ago 6.49% < -2% |
| Gross Margin: 83.67% > 18% (prev 0.48%; Δ 8319 % > 0.5%) |
| Asset Turnover: 88.73% > 50% (prev 60.35%; Δ 28.38% > 0%) |
| Interest Coverage Ratio: 1.47 > 6 (EBITDA TTM 563.9m / Interest Expense TTM 108.0m) |
Altman Z'' (< 1.1 .. > 2.6) 0.70
| A: 0.04 (Total Current Assets 1.14b - Total Current Liabilities 959.2m) / Total Assets 4.31b |
| B: -0.04 (Retained Earnings -161.3m / Total Assets 4.31b) |
| C: 0.04 (EBIT TTM 158.7m / Avg Total Assets 4.53b) |
| D: 0.30 (Book Value of Equity 835.5m / Total Liabilities 2.75b) |
| Altman-Z'' Score: 0.70 = B |
ValueRay F-Score (Strict, 0-100) 65.67
| 1. Piotroski: 6.0pt |
| 2. FCF Yield: 59.07% |
| 3. FCF Margin: 34.29% |
| 4. Debt/Equity: 1.34 |
| 5. Debt/Ebitda: -1.18 |
| 6. ROIC - WACC: 0.71% |
| 7. RoE: -7.40% |
| 8. Revenue Trend: -14.31% |
| 9. EPS Trend: -11.61% |
What is the price of UBI shares?
Over the past week, the price has changed by +5.95%, over one month by +4.77%, over three months by -19.27% and over the past year by -40.95%.
Is UBI a buy, sell or hold?
What are the forecasts/targets for the UBI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.3 | 40.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 4.5 | -31.7% |
UBI Fundamental Data Overview January 17, 2026
P/E Forward = 12.5156
P/S = 0.4853
P/B = 0.5389
P/EG = 2.3907
Revenue TTM = 4.02b EUR
EBIT TTM = 158.7m EUR
EBITDA TTM = 563.9m EUR
Long Term Debt = 1.59b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 359.6m EUR (from shortTermDebt, last quarter)
Debt = 2.09b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -668.2m EUR (from netDebt column, last quarter)
Enterprise Value = 2.34b EUR (914.9m + Debt 2.09b - CCE 668.4m)
Interest Coverage Ratio = 1.47 (Ebit TTM 158.7m / Interest Expense TTM 108.0m)
EV/FCF = 1.69x (Enterprise Value 2.34b / FCF TTM 1.38b)
FCF Yield = 59.07% (FCF TTM 1.38b / Enterprise Value 2.34b)
FCF Margin = 34.29% (FCF TTM 1.38b / Revenue TTM 4.02b)
Net Margin = -3.19% (Net Income TTM -128.3m / Revenue TTM 4.02b)
Gross Margin = 83.67% ((Revenue TTM 4.02b - Cost of Revenue TTM 656.9m) / Revenue TTM)
Gross Margin QoQ = 48.57% (prev 90.84%)
Tobins Q-Ratio = 0.54 (Enterprise Value 2.34b / Total Assets 4.31b)
Interest Expense / Debt = 2.30% (Interest Expense 48.1m / Debt 2.09b)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 119.0m (EBIT 158.7m * (1 - 25.00%))
Current Ratio = 1.18 (Total Current Assets 1.14b / Total Current Liabilities 959.2m)
Debt / Equity = 1.34 (Debt 2.09b / totalStockholderEquity, last quarter 1.56b)
Debt / EBITDA = -1.18 (Net Debt -668.2m / EBITDA 563.9m)
Debt / FCF = -0.48 (Net Debt -668.2m / FCF TTM 1.38b)
Total Stockholder Equity = 1.73b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.83% (Net Income -128.3m / Total Assets 4.31b)
RoE = -7.40% (Net Income TTM -128.3m / Total Stockholder Equity 1.73b)
RoCE = 4.78% (EBIT 158.7m / Capital Employed (Equity 1.73b + L.T.Debt 1.59b))
RoIC = 4.33% (NOPAT 119.0m / Invested Capital 2.75b)
WACC = 3.62% (E(914.9m)/V(3.00b) * Re(7.94%) + D(2.09b)/V(3.00b) * Rd(2.30%) * (1-Tc(0.25)))
Discount Rate = 7.94% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 3.19%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈1.38b ; Y1≈905.4m ; Y5≈413.1m
Fair Price DCF = 102.7 (EV 13.16b - Net Debt -668.2m = Equity 13.83b / Shares 134.7m; r=5.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: -11.61 | EPS CAGR: -6.58% | SUE: 0.0 | # QB: 0
Revenue Correlation: -14.31 | Revenue CAGR: -23.46% | SUE: 0.60 | # QB: 0
EPS current Year (2026-03-31): EPS=-0.89 | Chg30d=-0.563 | Revisions Net=-4 | Growth EPS=-58.4% | Growth Revenue=-2.5%
EPS next Year (2027-03-31): EPS=0.76 | Chg30d=-0.265 | Revisions Net=+1 | Growth EPS=+185.8% | Growth Revenue=+11.1%